IDXX
IDEXX Laboratories, Inc.
IDXX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over IDXX overall, supported by stronger modeled upside and stronger fundamentals.
IDXX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
IDXX's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IDXX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 43x | $634 | -9.1% |
| Forward | 43x | $698 | — |
| Current | 47x | $698 | — |
| Fair | 53x | $793 | +14% |
| Expensive | 72x | $1,066 | +53% |
Historical ranges are pointers, not guarantees.
IDXX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IDXX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for IDXX, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IDXX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $16.28 | +9.7% |
| Q3 2026 | $14.84 | +18% |
| Q2 2026 | $14.23 | +18% |
| Q1 2026 | $13.59 | +26% |
| Q4 2025 | $13.08 | +23% |
| Q3 2025 | $12.61 | +22% |
| Q2 2025 | $12.01 | +19% |
| Q1 2025 | $10.82 | +4.8% |
| Q4 2024 | $10.67 | +6.1% |
IDXX's earnings per share have climbed steadily: $14.84 over the past year, up 18% from the year before, and higher year over year for 14 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IDXX on earnings, with stronger typical year-over-year growth.
IDXX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +9.9% |
| Q2 2026 | $1.2B | +9.7% |
| Q1 2026 | $1.1B | +14% |
| Q4 2025 | $1.1B | +14% |
| Q3 2025 | $1.1B | +13% |
| Q2 2025 | $1.1B | +11% |
| Q1 2025 | $998.4M | +3.6% |
| Q4 2024 | $954.3M | +5.8% |
IDXX's revenue has grown year over year every quarter since late 2020: $1.2B last quarter, up 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +1 points |
| Q2 2026 | 35% | +1.4 points |
| Q1 2026 | 32% | +0.1 points |
| Q4 2025 | 29% | +1.5 points |
| Q3 2025 | 32% | +1 points |
| Q2 2025 | 34% | +7.3 points |
| Q1 2025 | 32% | +0.7 points |
| Q4 2024 | 27% | +0.2 points |
IDXX's operating margin was 33% last quarter, up 1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IDXX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IDXX on profitability, with a higher operating margin.
IDXX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $420.8M | +13% |
| Q2 2026 | $322.5M | +113% |
| Q1 2026 | $234.3M | +13% |
| Q4 2025 | $326.3M | +40% |
| Q3 2025 | $371.2M | +93% |
| Q2 2025 | $151.6M | -29% |
| Q1 2025 | $207.9M | +24% |
| Q4 2024 | $232.8M | +7.1% |
IDXX has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
IDXX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -263K shares |
| 1 year | -2% | -1.6M shares |
| 3 years | -5.9% | -4.9M shares |
| 5 years | -8.6% | -7.5M shares |
| Available history | -9.7% | -8.5M shares |
IDXX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $112.2M |
| Q2 2026 | $346.8M |
| Q1 2026 | $351M |
| Q4 2025 | $237.8M |
| Q3 2025 | $240.2M |
| Q2 2025 | $338.1M |
| Q1 2025 | $400.9M |
| Q4 2024 | $246M |
IDXX spent $1B buying back its own shares over the past year, down 14% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IDXX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.4x | Very low |
| Q4 2024 | 0.3x | Very low |
IDXX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IDXX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.3 | Overbought |
| Stochastic | 72.0 | Neutral |
IDXX's weekly RSI is 72 (overbought) and its Stochastic is 72 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IDXX PE vs Healthcare Sector
| Metric | IDXX | Sector median | Relative |
|---|---|---|---|
| PE | 47x | 26x | 82% above |
| PE % | 28 | 29 | 1 pt below |
IDXX is trading at 47x earnings, a 82% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over IDXX on valuation relative to its sector.
IDXX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $575.2 | 21% above |
| 20 week MA | $559.8 | 25% above |
| 50 week MA | $593.1 | 18% above |
| 100 week MA | $562.0 | 24% above |
| 200 week MA | $525.7 | 33% above |
IDXX is in an uptrend: it's above all five of its weekly moving averages, and 33% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
IDXX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $264.0 | $497.1 | +88% |
| 2021 | $497.1 | $645.0 | +30% |
| 2022 | $645.0 | $410.6 | -36% |
| 2023 | $410.6 | $555.1 | +35% |
| 2024 | $555.1 | $414.9 | -25% |
| 2025 | $414.9 | $688.5 | +66% |
| 2026 YTD | $688.5 | $698.0 | +1.4% |
IDXX has finished higher in four of the last six years, two of them by more than 50%. It's up 1.4% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IDXX on returns for 2026, with the stronger performance.